We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Dual Path Platform Assay Evaluated for Leptospirosis

By LabMedica International staff writers
Posted on 08 Mar 2018
Print article
Image: Representative non-reactive (A), strongly reactive (B) and weakly reactive (C) Dual Path Platform (DPP) assay results for leptospirosis (Photo courtesy of the Oswaldo Cruz Foundation).
Image: Representative non-reactive (A), strongly reactive (B) and weakly reactive (C) Dual Path Platform (DPP) assay results for leptospirosis (Photo courtesy of the Oswaldo Cruz Foundation).
Leptospirosis is an important global cause of acute fever and a leading cause of morbidity among zoonotic diseases and annually, more than one million cases and 50,000 deaths occur worldwide. Approximately 5% to10% of symptomatic patients develop severe manifestations, including multi-system dysfunction and 15% of these may die.

The gold standards for diagnosing leptospirosis, the microscopic agglutination test (MAT) and hemoculture, have limitations. MAT requires maintenance of reference Leptospira cultures and paired sera for diagnosis, and blood cultures are generally low yield. Early detection of leptospirosis with field-ready diagnostics may improve clinical management and mitigate outbreaks.

Scientists from the Oswaldo Cruz Foundation (Salvador, Brazil; www.bahia.fiocruz.br) and their colleagues sequentially enrolled 98 patients hospitalized for acute febrile illnesses, of which they confirmed 32 by leptospirosis reference tests. The patients were from a reference infectious diseases hospital and the specimens were collected from April 18 to October 18, 2012. The study compares the diagnostic accuracy and clinical utility of the point-of-care Dual Path Platform (DPP) using finger stick blood (FSB) against the serum DPP, venous whole blood (VWB) DPP, immunoglobulin-M enzyme-linked immunosorbent assay (IgM-ELISA), and clinical impression.

The DPP (Chembio Diagnostic Systems, Medford, New York, USA; www.chembio.com) utilizes a variation of lateral flow technology, whereby the biological sample and the colorimetric marker are separately delivered on perpendicular nitrocellulose membranes. The team found that DPP sensitivity for classic leptospirosis was 93% by FSB and 96% by VWB. Both POC assays were more sensitive than serum DPP (85%) and serum IgM-ELISA (81%), and similar to clinical impression (96%). The FSB and the VWB DPP detected 40% (2 of 5) and 80% (4 of 5) of the confirmed leptospiral meningitis, respectively, none of which clinicians suspected to be leptospirosis at triage. DPP specificity for classic leptospirosis was 80% by FSB and 75% by VWB.

The authors concluded that the FSB DPP is a rapid, portable alternative to laboratory-based diagnostics for the detection of severe leptospirosis. It expands the diagnostic landscape for effective clinical and outbreak management, and may improve detection of leptospirosis cases presenting with meningitis. The study was published on February 20, 2018, in the journal Public Library of Science Neglected Tropical Diseases.

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
New
Centromere B Assay
Centromere B Test

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.